ArticleFrontiers in molecular biosciences2026
Creatinine, leucine, and tetrahydrocorticosterone emerge as potential biomarkers for the diagnosis of sarcopenic osteoarthritis in middle-aged and elderly individuals: a cross-sectional exploratory study.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis is a common degenerative joint disease that is often associated with age-related muscle wasting known as sarcopenia, particularly in the elderly. This comorbid condition, referred to as "sarcopenic osteoarthritis", may have a distinct metabolic profile; however, specific serum biomarkers for this phenotype remain poorly characterized. Therefore, we conducted an untargeted serum metabolomics study to identify potential biomarkers of osteoarthritis in individuals with sarcopenia. Methods: This cross-sectional study enrolled 82 participants categorized into healthy controls, osteoarthritis, and sarcopenic osteoarthritis groups (n = 30, 30, 22). Fasting serum was analysed by untargeted LC-MS metabolomics. Differential metabolites were identified using multivariate statistics (PCA, PLS-DA; VIP >1) combined with univariate tests (P < 0.05, FDR-adjusted q < 0.05, |log Results: Metabolomic analyses distinguished sarcopenic osteoarthritis from osteoarthritis alone by significant alterations in steroid hormone biosynthesis and sphingolipid metabolism. We screened a total of 20 substances for use as biomarkers of sarcopenic osteoarthritis and ended up focusing mainly on three of them. Conclusion: Untargeted serum metabolomics successfully distinguished between healthy controls, osteoarthritis, and sarcopenic osteoarthritis and identified several candidate biomarkers. Creatinine, leucine, and tetrahydrocorticosterone emerged as promising biomarkers for the detection and phenotyping of the distinct sarcopenic osteoarthritis phenotype based on their clinical relevance and ease of measurement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.